Igaki Naoya, Matsuda Tomokazu, Yatani Hirofumi, Kawaguchi Takayuki, Kida Aritoshi, Yanase Kimihiko, Moriguchi Rintarou, Sakai Makoto, Tamada Fumihiko, Goto Takeo
Department of Internal Medicine, Takasago Municipal Hospital, 33-1 Kamimachi, Arai-cho, Takasago 676-8585, Japan.
Clin Exp Nephrol. 2003 Dec;7(4):306-10. doi: 10.1007/s10157-003-0251-1.
We report a patient with diabetic endstage renal disease with an initial platelet count of 17.6 x 10(4)/mm3 who developed type-II heparin-induced thrombocytopenia (HIT) during the induction period of hemodialysis (HD) when unfractionated heparin was used. Because the recognition of the condition and the treatment of this patient with HIT was unsatisfactory, she developed deep venous thrombosis, myocardial infarction, and occlusion of vascular access, at times of platelet counts of 4.1 x 10(4), 7.7 x 10(4), and 6.4 x 10(4)/mm3, respectively, with antibodies to heparin/platelet factor 4 complex. Unfortunately, we misjudged in our belief that the thromboembolic events might be associated with an underlying procoagulant state in diabetic nephrotic syndrome, rather than being associated with the clinical picture of HIT. This case report suggests that the clinician must consider HIT in the differential diagnosis for thromboembolic complications during the induction period of HD, because unfractionated heparin is the major anticoagulant used in HD.
我们报告了一名终末期糖尿病肾病患者,其初始血小板计数为17.6×10⁴/mm³,在使用普通肝素进行血液透析(HD)诱导期发生了II型肝素诱导的血小板减少症(HIT)。由于对该HIT患者的病情识别和治疗效果不佳,她在血小板计数分别为4.1×10⁴、7.7×10⁴和6.4×10⁴/mm³时,出现了深静脉血栓形成、心肌梗死和血管通路闭塞,并伴有肝素/血小板因子4复合物抗体。不幸的是,我们错误地认为血栓栓塞事件可能与糖尿病肾病综合征潜在的促凝状态有关,而不是与HIT的临床表现有关。本病例报告提示,临床医生在HD诱导期对血栓栓塞并发症进行鉴别诊断时必须考虑HIT,因为普通肝素是HD中使用的主要抗凝剂。